Related Experiment Video
Updated: Aug 24, 2026
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Radiation safety with yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy
1Cancer Outpatient Treatment Clinic, Hoag Cancer Center, Newport Beach, CA 92663, USA.
Objectives:
To present pertinent issues involved in radiation safety in radioimmunotherapy with 90Y ibritumomab tiuxetan.
Data Sources:
Published clinical trials of 90Y ibritumomab tiuxetan and secondary literature on radiation safety and radioimmunotherapy.
Conclusion:
Radioimmunotherapy with 90Y ibritumomab tiuxetan is safe and effective in the indicated population, and radiation safety requirements for caregivers and patients are minimal. Yttrium 90 ibritumomab is routinely and safety administered as an outpatient procedure; safety precautions are universal precautions, with the addition of acrylic shielding for the preparation and administration of the radiolabeled dose.
Implications For Nursing Practice:
Oncology nurses play a key role in the multidisciplinary team. By observing universal precautions, and advising patients to do the same, oncology nurses may facilitate the safe and effective administration of the ibritumomab tiuxetan regimen.
Related Concept Videos
01:13Radiological Investigation III: Pulmonary Angiogram and PET Scan
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...